Details for New Drug Application (NDA): 089025
✉ Email this page to a colleague
NDA 089025 describes PROPOXYPHENE COMPOUND 65, which is a drug marketed by Ivax Sub Teva Pharms, Sandoz, and Teva, and is included in three NDAs. Additional details are available on the PROPOXYPHENE COMPOUND 65 profile page.
The generic ingredient in PROPOXYPHENE COMPOUND 65 is aspirin; caffeine; propoxyphene hydrochloride. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; caffeine; propoxyphene hydrochloride profile page.
The generic ingredient in PROPOXYPHENE COMPOUND 65 is aspirin; caffeine; propoxyphene hydrochloride. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; caffeine; propoxyphene hydrochloride profile page.
Summary for 089025
| Tradename: | PROPOXYPHENE COMPOUND 65 |
| Applicant: | Teva |
| Ingredient: | aspirin; caffeine; propoxyphene hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 389MG;32.4MG;65MG | ||||
| Approval Date: | Mar 29, 1985 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
